These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29330067)

  • 1. Protein complexes as psychiatric and neurological drug targets.
    Kato AS; Witkin JM
    Biochem Pharmacol; 2018 May; 151():263-281. PubMed ID: 29330067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Auxiliary subunits of AMPA receptors: The discovery of a forebrain-selective antagonist, LY3130481/CERC-611.
    Kato AS; Witkin JM
    Biochem Pharmacol; 2018 Jan; 147():191-200. PubMed ID: 28987594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting voltage-gated calcium channels in neurological and psychiatric diseases.
    Zamponi GW
    Nat Rev Drug Discov; 2016 Jan; 15(1):19-34. PubMed ID: 26542451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of the First α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonist Dependent upon Transmembrane AMPA Receptor Regulatory Protein (TARP) γ-8.
    Gardinier KM; Gernert DL; Porter WJ; Reel JK; Ornstein PL; Spinazze P; Stevens FC; Hahn P; Hollinshead SP; Mayhugh D; Schkeryantz J; Khilevich A; De Frutos O; Gleason SD; Kato AS; Luffer-Atlas D; Desai PV; Swanson S; Burris KD; Ding C; Heinz BA; Need AB; Barth VN; Stephenson GA; Diseroad BA; Woods TA; Yu H; Bredt D; Witkin JM
    J Med Chem; 2016 May; 59(10):4753-68. PubMed ID: 27067148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism.
    Kato AS; Burris KD; Gardinier KM; Gernert DL; Porter WJ; Reel J; Ding C; Tu Y; Schober DA; Lee MR; Heinz BA; Fitch TE; Gleason SD; Catlow JT; Yu H; Fitzjohn SM; Pasqui F; Wang H; Qian Y; Sher E; Zwart R; Wafford KA; Rasmussen K; Ornstein PL; Isaac JT; Nisenbaum ES; Bredt DS; Witkin JM
    Nat Med; 2016 Dec; 22(12):1496-1501. PubMed ID: 27820603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMPA Receptor Positive Allosteric Modulators: Potential for the Treatment of Neuropsychiatric and Neurological Disorders.
    Reuillon T; Ward SE; Beswick P
    Curr Top Med Chem; 2016; 16(29):3536-3565. PubMed ID: 27363568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMPA Receptors as Therapeutic Targets for Neurological Disorders.
    Lee K; Goodman L; Fourie C; Schenk S; Leitch B; Montgomery JM
    Adv Protein Chem Struct Biol; 2016; 103():203-61. PubMed ID: 26920691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Determinants of the γ-8 TARP Dependent AMPA Receptor Antagonist.
    Lee MR; Gardinier KM; Gernert DL; Schober DA; Wright RA; Wang H; Qian Y; Witkin JM; Nisenbaum ES; Kato AS
    ACS Chem Neurosci; 2017 Dec; 8(12):2631-2647. PubMed ID: 28825787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The alpha2delta subunit of the voltage-dependent calcium channel. A new pharmaceutical target for psychiatry and neurology].
    Wedekind D; Bandelow B
    Nervenarzt; 2005 Jul; 76(7):888-91. PubMed ID: 15952008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update 1 of: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders.
    Ye N; Neumeyer JL; Baldessarini RJ; Zhen X; Zhang A
    Chem Rev; 2013 May; 113(5):PR123-78. PubMed ID: 23464812
    [No Abstract]   [Full Text] [Related]  

  • 11. Stargazin is an AMPA receptor auxiliary subunit.
    Vandenberghe W; Nicoll RA; Bredt DS
    Proc Natl Acad Sci U S A; 2005 Jan; 102(2):485-90. PubMed ID: 15630087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic disruption of voltage-gated calcium channels in psychiatric and neurological disorders.
    Heyes S; Pratt WS; Rees E; Dahimene S; Ferron L; Owen MJ; Dolphin AC
    Prog Neurobiol; 2015 Nov; 134():36-54. PubMed ID: 26386135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nicotine acetylcholine receptors and neuropsychiatric disorders].
    Vázquez-Palacios G; Bonilla-Jaime H
    Rev Neurol; 2004 Dec 16-31; 39(12):1146-60. PubMed ID: 15625635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.
    Lees GJ
    Drugs; 2000 Jan; 59(1):33-78. PubMed ID: 10718099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMPA receptors as drug targets in neurological disease--advantages, caveats, and future outlook.
    Chang PK; Verbich D; McKinney RA
    Eur J Neurosci; 2012 Jun; 35(12):1908-16. PubMed ID: 22708602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of human epileptic tissue in the characterization and development of novel antiepileptic drugs: The example of CERC-611 and KRM-II-81.
    Witkin JM; Ping X; Cerne R; Mouser C; Jin X; Hobbs J; Tiruveedhula VVNPB; Li G; Jahan R; Rashid F; Kumar Golani L; Cook JM; Smith JL
    Brain Res; 2019 Nov; 1722():146356. PubMed ID: 31369732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TARP auxiliary subunits switch AMPA receptor antagonists into partial agonists.
    Menuz K; Stroud RM; Nicoll RA; Hays FA
    Science; 2007 Nov; 318(5851):815-7. PubMed ID: 17975069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GABA(B) receptors and synaptic modulation.
    Kornau HC
    Cell Tissue Res; 2006 Nov; 326(2):517-33. PubMed ID: 16932937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Getting a Handle on Neuropharmacology by Targeting Receptor-Associated Proteins.
    Maher MP; Matta JA; Gu S; Seierstad M; Bredt DS
    Neuron; 2017 Dec; 96(5):989-1001. PubMed ID: 29216460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metabotropic glutamate receptors: new molecular targets in the treatment of neurological and psychiatric diseases].
    Luján-Miras R
    Rev Neurol; 2005 Jan 1-15; 40(1):43-53. PubMed ID: 15696426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.